Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

・It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats.

It took decades to develop the first treatments to address the root causes of Alzheimer’s disease, and when they first reached patients, they weren’t exactly convenient to take. Patients have to visit ...

Novo Nordisk (NVO) aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. (LLY), Bloomberg News reported. Currently ...

The maker of Wegovy and Ozempic announced that they’re slashing prices of its popular GLP-1 drugs by as much as 50%. Wegovy injections and pills currently cost $1,349.02 a month, while Ozempic and ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

Wegovy (semaglutide) does come in a pill form. In December of 2025, the Food and Drug Administration (FDA) approved Wegovy as an oral tablet. Wegovy injections and tablets contain the same active ...

A one-month, four-dose pen could reduce injector component consumption and assembly cycles, addressing a key constraint that has limited GLP-1 category supply reliability. Consolidation of doses may ...

The price of the popular GLP-1 medications will be cut, starting in January of 2027, manufacturer Novo Nordisk said in a statement Tuesday, Feb. 24 Shelby Knowles/Bloomberg/Getty The manufacturer of ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Still life of the high cost of drugs. Closeup of Ozempic and Wegovy injection pens with a ...

Novo Nordisk (NYSE: NVO) is taking it on the chin this morning, after revealing the latest clinical trial results for weight loss using its CagriSema drug (a 50-50 mix of amylin analog cagrilintide ...

Welcome to Camurus' Q4 Report 2025. [Operator Instructions] Now I'll hand the conference over to CEO, Fred Tiberg. Please go ahead. Thank you, Einar, and hello, everyone. Welcome to our fourth quarter ...